Non-fucosylated Anti-Human FGF23 Therapeutic Antibody, an ADCC-Enhanced Biobetter [Lot: CB20-PZ13] (CAT#: BioBet-013ZP) Datasheet

Target
FGF23
Isotype
Whole Human Antibody
Description
ADCC-enhanced Burosumab is a non-fucosylated anti-FGF23 therapeutic biobetter antibody. Creative Biolabs' Afuco™ technology platform allows for the control of glycosylation level, thereby achieving ADCC-Enhanced Anti-FGF23 Burosumab, a biobetter by reducing fucosylation of the Fc region of Burosumab, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
More specifically, the afucosylated therapeutic biobetter antibody was generated by recombinant DNA technology. It has been produced in CHO cells that are deficient for fucosylation and purified by affinity chromatography with protein G. The absence of the fucose residue from the N-glycans of IgG-Fc results in dramatic enhancement of antibody-dependent cellular cytotoxicity (ADCC).
Indication
X-linked hypophosphataemia
Classification
Therapeutic antibody; biobetter
Patent
Not Available
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Burosumab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
FGF23
Full Name
Fibroblast growth factor 23
Background
This gene encodes a member of the fibroblast growth factor family of proteins, which possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. The product of this gene regulates phosphate homeostasis and transport in the kidney. The full-length, functional protein may be deactivated via cleavage into N-terminal and C-terminal chains. Mutation of this cleavage site causes autosomal dominant hypophosphatemic rickets (ADHR). Mutations in this gene are also associated with hyperphosphatemic familial tumoral calcinosis (HFTC).
Alternative Names
ADHR; FGFN; HYPF; HFTC2; HPDR2; PHPTC
Gene ID
UniProt ID
Cellular Localization
Extracellular region or secreted
HGNC
OMIM
Involvement in Disease
Diseases associated with FGF23 include Hypophosphatemic Rickets, Autosomal Dominant and Tumoral Calcinosis, Hyperphosphatemic, Familial, 2.
Related Pathways
Its related pathways are RET signaling and Signaling by FGFR2 in disease.
Function
Regulator of phosphate homeostasis. Inhibit renal tubular phosphate transport by reducing the level of SLC34A1. Up-regulate the expression of EGR1 in the presence of KL (via similarity). Acts directly on the parathyroid glands, reducing parathyroid secretion (similar). Vitamin d metabolism regulator. Negatively regulate osteoblast differentiation and matrix mineralization.
Field of research
Cancer antibody; Controls and Markers antibody; Developmental Biology antibody; Signaling Transduction antibody
Post-translational modifications
1.Following secretion this protein is inactivated by cleavage into a N-terminal fragment and a C-terminal fragment. The processing is effected by proprotein convertases. 2.O-glycosylated by GALT3. Glycosylation is necessary for secretion; it blocks processing by proprotein convertases when the O-glycan is alpha 2,6-sialylated. Competition between proprotein convertase cleavage and block of cleavage by O-glycosylation determines the level of secreted active FGF23.
Trade name
Crysvita
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB14012
CAS number
1610833-03-8
Antibody Isotype
Whole Human Antibody
Antibody Clone
Burosumab
Description
Burosumab (KRN23) is a fully human monoclonal IgG1 antibody that specifically binds fibroblast growth factor 23 (FGF23). The U.S. Food and Drug Administration approved Burosumab for the treatment of X-linked hypophosphatemia (XLH) in 2018. It is a rare inherited disease that affects approximately 3,000 children and 12,000 adults in the United States. Burosumab is a breakthrough therapy classified as an orphan drug.
Indication
X-linked hypophosphataemia
Synonyms
KRN23
Burosumab (genetical recombination)
burosumab-twza
UNII
G9WJT6RD29

X-linked hypophosphatemia patients have low levels of circulating phosphorus in the blood. It can lead to impaired bone growth and development in children and adolescents, and can cause bone mineralization problems throughout life. Burosumab is a recombinant human monoclonal antibody (IgG1) that binds to and inhibits fibroblast growth factor 23 (FGF23). By inhibiting this growth factor, Burosumab increases the reabsorption of phosphate by the renal tubules in the kidney. Data from in vitro studies indicate that the body-dependent cytotoxicity (ADCC) would be mediated by burosumab.

Burosumab is used to treat patients with X-linked hypophosphatemia (XLH) aged 1 and older

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK